Precise insight from informative biomarkers for measurable residual disease (MRD) testing and tracking.
The myeloid malignancies acute myeloid leukemia (AML) is a genetically complex disease, with over 20,000 new diagnoses annually in the U.S. alone.1 Accurate molecular characterization and disease monitoring are foundational to risk stratification, treatment selection or personalized treatment, longterm surveillance, and informed decision making.
Why Prognostic Biomarkers Matter in Hematologic Malignancies
- Genomic profiling reveals genetic variants that:
- define disease type and anticipate disease trajectory
- inform risk stratification and prognosis
- predict therapeutic response
- inform eligibility for targeted therapies or clinical or clinical research trials
Key variants with established clinical importance include FLT3 and NPM1. Multiple menin-inhibitor trials are also highlighting the emerging importance of identifying KMT2A fusions.
In-House Assay Solutions
Software Solutions
Invivoscribe’s MRD testing suite empowers modern laboratories and researchers with standardized and objective tools that enable confident, date-driven disease monitoring and research applications.
1. https://seer.cancer.gov/statfacts/html/amyl.html. Accessed 23 February 2026.
